课题基金 / 基金详情

Identification Of A Complex Involved In Werner Syndrome

Identification Of A Complex Involved In Werner Syndrome
维尔纳综合征相关复合体的鉴定
批准号:
6815266
负责人:
Weidong Wang
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

Weidong Wang的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Werner Syndrome (WS) is a rare human genetic disease with many features of premature aging. It has been considered by many researchers as a useful model for human aging studies. The gene involved in WS has recently been cloned and was named WRN. It encodes a protein homologous to RecQ family of helicases. Indeed, the recombinant WRN protein produced using a baculovirus expression system contains a DNA helicase activity as well as an exonuclease activity. Interestingly, analysis of different WS patients suggests that some WRN mutations may impair the interactions between WRN and other proteins. This raised the possibility that WRN functions within a multisubunit protein complex in vivo. We have successfully purified one such complex and identified all its subunits by microsequencing. We found that this complex contains DNA-PKcs, Ku86, and Ku70 proteins. All these WRNp partners have previously been shown to participate in repair of DNA damage and in signaling pathways leading to cell cycle arrest and cell death. Our results are consistent with several publications from other groups which also found the interaction between WRNp and these proteins. Recently, we have used a different WRNp antibody and isolated a different form of the WRN complex, This new complex contains not only the DNA-PKcs, but also several novel proteins. One of them appears to be an interacting protein for lamin. One form of lamin, lamin-A, has been found to be defective in Hutchinson-Gilford progeria. We are speculating that this interacting protein may play a common role in premature aging from both diseases, and are currently investigating this connection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment
Developing proinsulin misfolding inhibitors for beta cell protection and diabetes treatment
Preclinical Validation of PPARg Acetylation Inhibitors for Diabetes Prevention and Treatment
Cytoprotection and the mechanism of action of a natural product Khellin against ER stress
海外基金